Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Annexin A5
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promising Signals of Effect in Annexin's RVO-Study
Details : ANXV (Annexin A5) shows a very clear desirable effect when used as a treatment against retinal vein occlusion and vascular inflammation in animal models.
Product Name : ANXV
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 08, 2023
Lead Product(s) : Annexin A5
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Annexin A5
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Treated in the Second Dose Group in Annexin's RVO study
Details : ANXV is an investigational new drug containing the human protein Annexin A5, produced by recombinant techniques in the bacteria Escherichia Coli (E.coli). ANXV can protect cells, reduce adhesive properties and influence the actions by immune cells.
Product Name : ANXV
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : Annexin A5
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
